-
公开(公告)号：US20060246009A1
公开(公告)日：2006-11-02
申请号：US11381079
申请日：2006-05-01
申请人： Sherry Morissette , Mark Tawa , Mark Oliveira
发明人： Sherry Morissette , Mark Tawa , Mark Oliveira
IPC分类号： A61K31/4745 , C07D491/08 , A61K9/14
CPC分类号： C07D451/10
摘要： The invention relates to new crystalline forms of tiotropium bromide, processes for preparing them and their use for preparing a pharmaceutical composition for the treatment of respiratory complaints, particularly for the treatment of COPD (chronic obstructive pulmonary disease) and asthma.
摘要翻译： 本发明涉及噻托溴铵的新结晶形式，其制备方法及其用于制备用于治疗呼吸道疾病，特别是用于治疗COPD（慢性阻塞性肺疾病）和哮喘的药物组合物的用途。
-
公开(公告)号：US08362062B2
公开(公告)日：2013-01-29
申请号：US10541216
申请日：2003-12-24
申请人： Mark Tawa , Julius Remenar , Matthew L. Peterson , Örn Almarsson , Hector Guzman , Hongming Chen , Mark Oliveira
发明人： Mark Tawa , Julius Remenar , Matthew L. Peterson , Örn Almarsson , Hector Guzman , Hongming Chen , Mark Oliveira
CPC分类号： A61K9/1652 , A61K9/145 , A61K9/146 , A61K31/18 , A61K31/365 , A61K31/415 , A61K31/635 , A61K47/10 , A61K47/32 , C07D231/12
摘要： The invention relates to methods of screening mixtures containing a pharmaceutical compound and an excipient to identify properties of the pharmaceutical compound/excipient combination that retard solid-state nucleation. The invention further relates to increasing the solubility, dissolution and bioavailability of a drug with low solubility in gastric fluids conditions by combining the drug with a precipitation retardant and an optional enhancer.
摘要翻译： 本发明涉及筛选含有药物化合物和赋形剂的混合物的方法，以鉴定延缓固态成核的药物化合物/赋形剂组合的性质。 本发明还涉及通过将药物与降凝剂和任选的增强剂组合来增加在胃液条件下具有低溶解度的药物的溶解度，溶解度和生物利用度。
-
公开(公告)号：US20050025791A1
公开(公告)日：2005-02-03
申请号：US10601092
申请日：2003-06-20
申请人： Julius Remenar , Matthew Peterson , Orn Almarsson , Hector Guzman , Hongming Chen , Mark Tawa , Mark Oliveira
发明人： Julius Remenar , Matthew Peterson , Orn Almarsson , Hector Guzman , Hongming Chen , Mark Tawa , Mark Oliveira
IPC分类号： A61K9/14 , A61K9/16 , A61K9/64 , A61K31/18 , A61K31/365 , A61K31/415 , A61K31/635 , A61K47/10 , A61K47/32 , C07B63/00 , G01N21/27 , G01N25/08 , G01N25/12 , G01N33/15 , A61K9/00
CPC分类号： A61K9/1652 , A61K9/145 , A61K9/146 , A61K31/18 , A61K31/365 , A61K31/415 , A61K31/635 , A61K47/10 , A61K47/32 , C07D231/12
摘要： The invention relates to methods of screening mixtures containing a pharmaceutical compound and an excipient to identify properties of the pharmaceutical compound/excipient combination that retard solid-state nucleation. The invention further relates to increasing the solubility, dissolution and bioavailability of a drug with low solubility in gastric fluids conditions by combining the drug with a recrystallization/precipitation retardant and an optional enhancer.
摘要翻译： 本发明涉及筛选含有药物化合物和赋形剂的混合物的方法，以鉴定延缓固态成核的药物化合物/赋形剂组合的性质。 本发明还涉及通过将药物与重结晶/沉淀阻滞剂和任选的增强剂组合来增加在胃液条件下溶解度低的药物的溶解度，溶解度和生物利用度。
-
公开(公告)号：US20060134198A1
公开(公告)日：2006-06-22
申请号：US10541216
申请日：2003-12-24
申请人： Mark Tawa , Julius Remenar , Matthew Peterson , Orn Almarsson , Hector Guzman , Hongming Chen , Mark Oliveira
发明人： Mark Tawa , Julius Remenar , Matthew Peterson , Orn Almarsson , Hector Guzman , Hongming Chen , Mark Oliveira
IPC分类号： A61K9/20
CPC分类号： A61K9/1652 , A61K9/145 , A61K9/146 , A61K31/18 , A61K31/365 , A61K31/415 , A61K31/635 , A61K47/10 , A61K47/32 , C07D231/12
摘要： The invention relates to methods of screening mixtures containing a pharmaceutical compound and an excipient to identify properties of the pharmaceutical compound/excipient combination that retard solid-state nucleation. The invention further relates to increasing the solubility, dissolution and bioavailability of a drug with low solubility in gastric fluids conditions by combining the drug with a precipitation retardant and an optional enhancer.
-
公开(公告)号：US20060052432A1
公开(公告)日：2006-03-09
申请号：US10528244
申请日：2003-09-16
申请人： Julius Remenar , Matthew Peterson , Orn Almarsson , Hector Guzman , Hongming Chen , Mark Tawa , Mark Oliveira
发明人： Julius Remenar , Matthew Peterson , Orn Almarsson , Hector Guzman , Hongming Chen , Mark Tawa , Mark Oliveira
IPC分类号： A61K9/00 , A61K31/18 , A61K31/415 , A61K31/365
CPC分类号： A61K9/0019 , A61K9/145 , A61K9/146 , A61K31/18 , A61K31/365 , A61K31/415 , A61K31/635 , A61K47/10
摘要： The invention relates to methods of screening mixtures containing a pharmaceutical compound and an excipient to identify properties of the pharmaceutical compound/excipient combination that retard solid-state nucleation. The invention further relates to increasing the solubility, dissolution and bioavailability of a drug with low solubility in gastric fluids conditions by combining the drug with a precipitation retardant and an optional enhancer.
-
公开(公告)号：US20100210731A1
公开(公告)日：2010-08-19
申请号：US12708998
申请日：2010-02-19
IPC分类号： A61K31/165 , C07C233/11 , A61P25/00 , A61P25/16 , A61P25/28
CPC分类号： C07C317/50 , A61K31/165 , C07C317/44
摘要： Polymorphs and solvates of racemic, enantiomerically pure, and enantiomerically mixed modafinil are formed and discussed. In addition, said forms are described as useful for the treatment of many conditions including, but not limited to, narcolepsy.
摘要翻译： 形成和讨论了外消旋，对映异构体纯和对映体混合的莫达非尼的多晶型物和溶剂合物。 此外，所述形式被描述为可用于治疗许多病症，包括但不限于发作性睡病。
-
公开(公告)号：US07566805B2
公开(公告)日：2009-07-28
申请号：US10570405
申请日：2004-09-04
IPC分类号： C07C323/22 , A61K31/165
CPC分类号： C07C317/38
摘要： Co-crystals and solvates of racemic, enantiomerically pure, and enantiomerically mixed modafinil are formed and several important physical properties are modulated. The solubility, dissolution, bioavailability, dose response, and stability of modafinil can be modulated to improve efficacy in pharmaceutical compositions.
摘要翻译： 形成外消旋，对映异构体纯和对映异构体混合的莫达非尼的共晶体和溶剂合物，并调制几种重要的物理性质。 可以调节莫达非尼的溶解度，溶解度，生物利用度，剂量反应和稳定性，以提高药物组合物的功效。
-
公开(公告)号：US08338646B2
公开(公告)日：2012-12-25
申请号：US12708998
申请日：2010-02-19
IPC分类号： C07C233/65
CPC分类号： C07C317/50 , A61K31/165 , C07C317/44
摘要： Polymorphs and solvates of racemic, enantiomerically pure, and enantiomerically mixed modafinil are formed and discussed. In addition, said forms are described as useful for the treatment of many conditions including, but not limited to, narcolepsy.
摘要翻译： 形成和讨论了外消旋，对映异构体纯和对映体混合的莫达非尼的多晶型物和溶剂合物。 此外，所述形式被描述为可用于治疗许多病症，包括但不限于发作性睡病。
-
公开(公告)号：US20090018202A1
公开(公告)日：2009-01-15
申请号：US10587086
申请日：2005-02-01
IPC分类号： A61K31/165 , C07C231/00 , A61P25/00
CPC分类号： C07C317/50 , A61K31/165 , C07C317/44
摘要： Polymorphs and solvates of racemic, enantiomerically pure, and enantiomerically mixed modafinil are formed and discussed. In addition, said forms are described as useful for the treatment of many conditions including, but not limited to, narcolepsy.
摘要翻译： 形成和讨论了外消旋，对映异构体纯和对映体混合的莫达非尼的多晶型物和溶剂合物。 此外，所述形式被描述为可用于治疗许多病症，包括但不限于发作性睡病。
-
10.发明申请Novel Isovaleramide Forms, Compositions Thereof, and Related Methods of Use 审中-公开新型异戊酰胺形式，组合物及相关使用方法公开(公告)号：US20080287542A1
公开(公告)日：2008-11-20
申请号：US11912759
申请日：2006-04-27
申请人： Mark Oliveira , Matthew Peterson
发明人： Mark Oliveira , Matthew Peterson
IPC分类号： A61K31/195 , A61P25/24 , A61P25/18 , A61P25/00
CPC分类号： C07C233/05 , C07C59/265
摘要： The invention provides novel isovaleramide forms. These forms include isovaleramide co-crystals, and solvates, hydrates, co-crystals, and polymorphs thereof. The invention also provides novel compositions comprising these novel forms and one or more suitable carriers. The invention also provides related methods of treatment or prevention. Compositions and methods of the invention have a number of uses, including the treatment or prevention of epilepsy and anxiety.
摘要翻译： 本发明提供新的异戊酰胺形式。 这些形式包括异戊酰胺共晶体，溶剂合物，水合物，共晶体及其多晶型物。 本发明还提供了包含这些新颖形式和一种或多种合适载体的新型组合物。 本发明还提供相关的治疗或预防方法。 本发明的组合物和方法具有许多用途，包括治疗或预防癫痫和焦虑。
-
-
-
-
-
-
-
-
-
搜索结果
17 条记录 (耗时 0.026 秒)
